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Abstract
Rationale Sexual side effects are commonly associated with
selective serotonin reuptake inhibitor (SSRI) treatment. Some
evidence suggest that activation of 5-HT1A receptors attenu-
ates SSRI-induced sexual dysfunction.
Objective This study in male rats compared the effects of
vilazodone, an antidepressant with SSRI and 5-HT1A receptor
partial agonist activity, with other prototypical SSRIs (citalopram
and paroxetine) on sexual behaviors and 5-HTreceptors (5-HT1A
and 5-HT2A) and transporter (5-HTT) levels in select forebrain
regions of the limbic system using quantitative autoradiography.
Methods Rats received vilazodone (1, 3, and 10 mg/kg),
citalopram (10 and 30 mg/kg), or paroxetine (10 mg/kg) treat-
ment for 14 days. Sexual behaviors (frequency and latency of
mounts, intromissions, and ejaculations) were measured in the
presence of an estrous female rat on days 1 (acute), 7 (sub-
chronic), and 14 (chronic).
Results Vilazodone-treated rats exhibited no sexual dysfunc-
tion compared with controls; in contrast, the citalopram- and
paroxetine-treated rats exhibited impaired copulatory and
ejaculatory behaviors after subchronic and chronic treatments.
Chronic vilazodone treatment markedly decreased 5-HT1A
receptor levels in cortical and hippocampal regions, while
the SSRIs increased levels of this receptor in similar regions.
All chronic treatments reduced 5-HTT levels across the fore-
brain; however, the magnitude of the decrease was consider-
ably smaller for vilazodone than for the SSRIs.
Conclusions The current studies showed that chronic treat-
ment with vilazodone, in contrast to citalopram and paroxe-
tine, was not associated with diminished sexual behaviors in
male rats, which may be related to the differential effects of
vilazodone on 5-HT1A receptor and 5-HTT levels relative to
conventional SSRIs.
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Introduction
Major depressive disorder (MDD) is one of the most common
mental disorders, with an estimated lifetime prevalence in the
USA of 19.2 % (Kessler et al. 2010). Selective serotonin re-
uptake inhibitors (SSRIs) are efficacious in treating MDD and
are the most commonly prescribed first-line therapy.
However, their clinical effectiveness is often limited by poor
adherence and discontinuation due to lack of therapeutic re-
sponse and adverse effects (Nantz et al. 2009). Sexual dys-
function, which affects up to 60 % of patients treated with
SSRIs (Kennedy and Rizvi 2009), is a leading cause of treat-
ment nonadherence (Ashton et al. 2005) and is reported by
patients to be one of the most unacceptable side effects asso-
ciated with SSRIs (Hu et al. 2004). Therefore, reducing the
incidence and burden of sexual dysfunction associated with
SSRIs is important in improving clinical outcomes in patients
with MDD.
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Approaches to mitigating the sexual dysfunction asso-
ciated with SSRI treatment include lowering dosage,
switching antidepressant medications, or adding concom-
itant medications such as a phosphodiesterase inhibitor
type 5 (PDE5; e.g., sildenafil), a norepinephrine-
dopamine reuptake inhibitor (e.g., bupropion), or a 5-
HT1A receptor partial agonist (e.g., buspirone) (Rizvi
and Kennedy 2013). Clinical and preclinical evidence
supports a role for the 5-HT1A receptor in regulating sex-
ual behavior. Buspirone was shown to improve sexual
function in depressed patients that were experiencing sex-
ual dysfunction while taking the SSRIs paroxetine and
citalopram (Landen et al. 1999). In male rats, buspirone
and full 5-HT1A receptor agonists (8-OH-DPAT and
flesinoxan) promoted sexual behavior by decreasing ejac-
ulation latencies (Chan et al. 2010; Snoeren et al. 2014).
In contrast, the 5-HT1A receptor antagonist WAY-100635
inhibited sexual behavior when it was coadministered
with citalopram (de Jong et al. 2005a) or paroxetine
(Looney et al. 2005) and when administered in 5-HTT
knockout rats (Chan et al. 2011). These studies suggest
that 5-HT1A receptor antagonism only inhibits sexual be-
haviors under conditions of chronically elevated serotonin
(5-HT) (Olivier et al. 2011).
Vilazodone is an SSRI and 5-HT1A receptor partial
agonist (Dawson and Watson 2009) approved by the
Food and Drug Administration (FDA) for the treatment
of MDD in adults (Forest 2011). Efficacy for vilazodone
in adults with MDD was demonstrated in two pivotal
trials (Khan et al. 2011; Rickels et al. 2009); safety
was further supported in a 52-week open-label study
(Robinson et al. 2011). Vilazodone treatment was associ-
ated with relatively low adverse impact on sexual func-
tion relative to the high prevalence of sexual dysfunction
in patients at baseline (Clayton et al. 2013). Limited
evidence from these clinical trials in MDD has shown
that the incidence of sexual dysfunction was similar be-
tween patients treated with vilazodone and patients treat-
ed with placebo, suggesting that vilazodone may be as-
sociated with less sexual dysfunction than other SSRIs
(Clayton et al. 2013).
The mechanism by which 5-HT1A receptor agonists
affect sexual behavior is not well understood. Previous
evidence showing that 5-HT1A receptor agonists can
stimulate male sexual function (Blier and Ward 2003;
Chan et al. 2010; Snoeren et al. 2014) suggests that
the clinical advantages of vilazodone may in part be
mediated through its activity at the 5-HT1A receptor.
This study compared the effects of vilazodone treatment
and other SSRIs on copulatory and ejaculatory behav-
iors, as well as on brain 5-HT receptor and transporter




Male and female Wistar rats (Charles River Laboratories,
Germany), initially weighing 250-300 g, were group housed
(4 per cage) and maintained under reversed 12/12 h day/night
cycles (lights off 7:00 a.m.; lights on 7:00 p.m.); food and
water were available ad libitum. Estrus was induced in female
rats by a single injection of 50 μg estradiol benzoate dissolved
in sesame oil 36 to 42 h before testing with a male rat. Animals
were weighed on days 1, 7, and 14 of the drug experiment. All
behavioral experiments, including the drug administrations,
were reviewed and approved by Utrecht University’s animal
welfare committee (DEC).
Drugs
Vilazodone hydrochloride (1, 3, 10 mg/kg) and citalopram
hydrochloride (10, 30 mg/kg) were received from Forest
Laboratories, LLC. Paroxetine (10 mg/kg) was obtained from
a local pharmacy (20 mg tablet, Hexal Pharma Nederland BV)
and crushed into powder form. All drugs were dissolved or
suspended in vehicle (1 % methylcellulose and water) and
were administered orally (PO) at a dose volume of 2 mL/kg.
Sexual behavior test
The sexual behavior test was performed as previously de-
scribed (Chan et al. 2010). Briefly, estrus was induced in female
rats with estradiol injection 36 to 42 h before testing. Male rats
were placed in an observation cage (30×40×60 cm) for a 30-
min habituation period. Following the habituation period, an
estrous female was placed in the cage and video recording
commenced for 30 min. The frequencies of mounts (no vaginal
penetration), intromissions (vaginal penetration), and ejacula-
tions, and the latency to the first ejaculation (time between first
mount to ejaculation) were measured and scored during the 30-
min test using Observer® 5.0 (Noldus, Wageningen,
The Netherlands). Copulatory efficiency was defined as [num-
ber of intromissions / (number of intromissions+number of
mounts)]×100 %. Data from the first ejaculation series, which
included all events occurring before the first ejaculation, were
reported for mounting frequency, ejaculation latency, and cop-
ulatory efficiency. The ejaculation frequency for the entire 30-
min test was reported. All assessments were performed in the
dark phase of the light/dark cycle under dim red light
conditions.
Sexual training and the selection of male rats
In order to achieve stable sexual behavior, male rats (N=145)
were trained once per week for five consecutive weeks
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(pretreatment) against an estrous female in an observation
cage. Male rats that exhibited an ejaculation frequency of 2–
3 per 30-min test in the final two of the five training sessions
were classified as normal-performers (Pattij et al. 2005) and
were included in the drug studies (n=98).
Experimental design
Sexual behavior test
Normal-performingmale rats were randomly divided into sev-
en treatment groups (n=14/group): vehicle, vilazodone 1 mg/
kg, vilazodone 3 mg/kg, vilazodone 10 mg/kg, citalopram
10 mg/kg, citalopram 30 mg/kg, and paroxetine 10 mg/kg.
All treatments were administered once daily for 14 days, ei-
ther 1 h before the sexual test or around 11:00 a.m. on days
without a sex test. The evaluations of sexual behaviors were
performed on day 1 (acute), day 7 (subchronic), and day 14
(chronic).
Animal treatment and tissue preparation
Following the chronic (14 days) treatment with vilazodone (3,
10 mg/kg), citalopram (10 mg/kg), paroxetine (10 mg/kg), or
vehicle (1%methylcellulose and water) and the day 14 sexual
behavior tests, n=8 animals per treatment group were ran-
domly chosen for the autoradiography experiments. Rats were
decapitated, and their brains were rapidly excised and stored at
−80 °C. Next, coronal sections (10 μm) were cut on a cryostat
at −20 °C and stored at −80 °C. Brain tissue from regions that
are thought tomediate neural pathways and behaviors (and are
typically disturbed in MDD patients) were selected for evalu-
ation (Baldessarini 2006). The following brain regions select-
ed for quantitative autoradiography: medial prefrontal cortex
(MPC), dorsolateral frontal cortex (DFC), medial caudate pu-
tamen (CP-M), lateral caudate putamen (CP-L), nucleus ac-
cumbens (NAc), hippocampus CA1 region (HIPP-CA1), hip-
pocampus CA3 region (HIPP-CA3), and entorhinal cortex
(EC).
Autoradiography assays
Serotonin transporter (5-HTT) levels were determined as pre-
viously described (Zhang et al. 2002). First, sections were
preincubated for 2 h at 4 °C in 50 mM Tris-HCl buffer
(pH 7.4) containing 120 mM NaCl. Next, sections were incu-
bated for 24 h at room temperature (RT) with fresh buffer
containing 1 nM [3H]cyanoimipramine (5-HTT ligand) and
the nonspecific binding (NSB) agent 5 mM sertraline.
Following incubation, sections were washed twice for
30 min in ice-cold buffer, rinsed in water, and air dried.
5-HT1A receptor levels were determined as previously de-
scribed (Tarazi et al. 2002). Sections were preincubated for
60 min at RT in 50 mM Tris-HCl buffer (pH 7.6) containing
ascorbic acid (0.1 %, w/v), 4 mM CaCl2, and 10 μM pargy-
line-HCl. Next, sections were incubated for 1 h at RT with
fresh buffer containing 2.0 nM [3H]8-OH-DPAT and 1 μM
5-HT as the NSB agent. Following incubation, sections were
washed twice for 5 min in ice-cold buffer, rinsed in water, and
air dried.
5-HT2A receptor levels were determined as previously de-
scribed (Tarazi et al. 2002). Sections were preincubated for 1 h
at RT in 50 mM Tris-HCl buffer (pH 7.7). Next, sections were
incubated for 1 h at RT in fresh buffer containing 3.0 nM
[3H]ketanserin, 1 μM prazosin, and 100 nM tetrabenzine with
the NSB 1 μM methysergide. Following the incubation, sec-
tions were washed twice for 30 min in ice-cold buffer, rinsed
in water, and air-dried.
For image analysis, radiolabeled slides and calibrated
[3H]standards (Amersham) were exposed to Biomax MR
films for 5–6 weeks at 4 °C. The films were developed and
fixed in Kodak D-19 for 5 min at RT. Optical density (OD) in
brain regions of interest was measured with a computerized
densitometric image analyzer (MCID-4 system, Imaging
Research; St. Catharines, Ontario). OD was converted to
nCi/mg of tissue with calibrated [3H]standards. After
subtracting nonspecific binding from total binding, the specif-
ic binding was determined and expressed as femtomole bound
per milligram tissue.
Statistical analysis
All behavioral data were analyzed by analysis of variance
(ANOVA; SPSSv22.0) to test for overall significance. If over-
all significant effects were found, post hoc Dunnett t tests were
used to evaluate differences between active- and vehicle-
treatment groups on the same experimental day. Data from
the autoradiography assays were analyzed using a two-way
ANOVA to evaluate changes across treatments and brain re-
gions for each assay. In case of overall statistically significant
effects for drug or brain region, post hoc Dunnett t tests were
used to evaluate differences between treatment and vehicle
groups. All significance testing was two-sided at the P< .05





On day 1, the vehicle-treated rats displayed an average of 2.5
ejaculations. Following acute administrations of vilazodone,
citalopram, and paroxetine, there were no significant effects of
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treatment on any of the sexual behavior parameters (Figs. 1
and 2a–b)
Day 7/subchronic administration
There were no differences in vehicle-treated rats on day 7
compared with day 1, indicating stable endophenotypes of
the sexual behavior parameters.
For the day 7 tests, there were significant effects of treat-
ment on mount frequency (F6, 91= 5.52; P< .001), copulatory
efficiency (F6, 91=5.61; P< .001), latency to first ejaculation
(F6, 91 = 12.65; P< .001), and ejaculation frequency (F6,
91 = 3.94; P = .002). Post hoc comparisons showed that
vilazodone-treated rats did not display any significant differ-
ences from vehicle-treated rats in sexual behavior after 7 days
of treatment. In contrast, citalopram-treated rats displayed in-
creased latency to ejaculation and decreased ejaculation fre-
quency compared with vehicle-treated controls (P < .05)
(Fig. 2a–b). Paroxetine-treated rats displayed significantly im-
paired sexual behavior on all measures after 7 days of treat-
ment (P< .05) (Figs. 1 and 2).
Day 14/chronic administration
Representative traces of individual rat scores for mounts, in-
tromissions, and ejaculations during the 30-min sex test on
day 14 (i.e., chronic treatment) are shown in Fig. 3.
On day 14, there were significant effects of treatment for
mount frequency (F6, 91= 3.59; P= .003), copulatory efficien-
cy (F6, 91 = 3.83; P= .002), latency to first ejaculation (F6,
91=4.10; P= .001), and ejaculation frequency (F6, 91=5.88;
P< .001). Similar to the previous test days, vilazodone-treated
rats did not display any differences in the sexual behaviors
compared with vehicle-treated rats. In contrast, citalopram-
treated rats had an increase in mount frequency (P< .05;
10 mg/kg) yet decreased ejaculation frequency and copulatory
efficiency (P < .05; 10 and 30 mg/kg) (Figs. 1 and 2b).
Paroxetine-treated rats displayed no differences in mount fre-
quency and ejaculation latency compared to vehicle-treated
rats; however, ejaculation frequency and copulatory efficiency
were decreased (P< .05) (Figs. 1 and 2).
During the day 14 sex test, the number of rats exhibiting 1,
2, 3, or 4 ejaculations was comparable following chronic
Fig. 1 Effects of vilazodone, citalopram, and paroxetine on first series
copulatory behavior in male rats. Effects of vilazodone (1, 3, and 10 mg/
kg), citalopram (10 and 30mg/kg), and paroxetine (10mg/kg) on amount
frequency and b copulatory efficiency (defined as number of
intromissions / [number of intromissions + number of mounts]) × 100 %
during the first ejaculatory series of the 30-min sex conducted after treat-
ment on day 1 (acute), day 7 (subchronic), and day 14 (chronic) in male
Wistar rats (n = 14/drug/dose). Data are shown as the mean ± SEM.
*P< .05 compared with vehicle
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treatment with vilazodone (10 mg/kg; single dose tested) or
vehicle, suggesting that chronic vilazodone treatment had no
adverse effects on ejaculations. Chronic treatment with
citalopram or paroxetine resulted in fewer rats having 1, 2,
3, or 4 ejaculations during the test than rats treated with vehi-
cle or vilazodone, suggesting that these treatments adversely
affected ejaculation frequency (Fig. 2c).
5-HT1A receptor levels
In vilazodone-treated rats, 5-HT1A receptor levels were re-
duced in the MPC, HIPP-CA1, HIPP-CA3, and EC regions
(P < .05) (Fig. 4a, Table 1). In contrast, citalopram- and
paroxetine-treated rats had increased 5-HT1A receptor levels
in the HIPP-CA1, HIPP-CA3, and EC regions (P < .05)
Fig. 2 Effects of vilazodone, citalopram, and paroxetine on ejaculatory
behavior in male rats. Effects of vilazodone (1, 3, and 10 mg/kg),
citalopram (10 and 30 mg/kg), and paroxetine (10 mg/kg) on a first
ejaculation latency and b total ejaculation frequency during the 30-min
sex tests conducted after treatment on day 1 (acute), day 7 (subchronic),
and day 14 (chronic) in male Wistar rats (n = 14/drug/dose). Data are
shown as the mean± SEM. *P< .05 compared with vehicle. c The num-
ber of rats (n= 14/group) that had 1, 2, 3, or 4 ejaculations during the 30-
min sexual behavior test on day 14
Psychopharmacology (2016) 233:1025–1034 1029
(Fig. 4a, Table 1). Notably, vilazodone showed the opposite
effects of citalopram or paroxetine on 5-HT1A receptor levels
in HIPP-CA1, HIPP-CA3, and EC brain regions.
5-HT2A receptor levels
Vilazodone-treated rats had increased 5-HT2A receptor levels
in the MPC and the DFC (10 mg/kg only) regions (P< .05)
(Fig. 4b, Table 1). Similarly, paroxetine-treated rats had in-
creased 5-HT2A receptor levels in the MPC and DFC regions
(P< .05) (Fig. 4b, Table 1). Citalopram-treated rats had in-
creased 5-HT2A receptor levels in the DFC region (P< .05)
(Fig. 4b, Table 1).
Serotonin transporter (5-HTT) levels
Chronic treatment with vilazodone, citalopram, and paroxe-
tine reduced 5-HTT levels in all brain regions (Fig. 4c, Table
1). Compared with vehicle, chronic vilazodone-treated (3 and
10 mg/kg/day) rats had dose-dependent reductions of 5-HTT
levels in the MPC, DFC, NAc, CPu, HIPP-CA1, HIPP-CA3,
and EC regions (P< .05). Chronic citalopram- and paroxetine-
treated rats (10 mg/kg/day for both) also had reductions in 5-
HTT levels compared to vehicle (P< .05); the magnitude of
reductions in 5-HTT levels was greater for citalopram- and
paroxetine-treated rats than for rats treated with both doses
of vilazodone (P< .05).
Discussion
The current studies compared the effects of vilazodone, a
combined SSRI and 5-HT1A receptor partial agonist, and con-
ventional SSRIs (citalopram and paroxetine) on male rat sex-
ual behaviors and brain 5-HT receptor and transporter levels.
SSRI treatment has been associated with dysfunction of the
three sequential aspects of the sexual response cycle: sexual
desire (i.e., libido), arousal (i.e., erectile function in men), and
orgasm (Serretti and Chiesa 2009). Rats also exhibit a sexual
response cycle, which includes introductory, copulatory, and
ejaculatory phases, that is sensitive to SSRI treatment
(Snoeren et al. 2014).
Vilazodone treatment had no adverse effects on copulatory
and ejaculatory behaviors following acute, subchronic
(7 days), and chronic (14 days) treatment; however, subchron-
ic and chronic treatment with paroxetine, and to a lesser extent
Fig. 3 Representative traces of individual sexual function after chronic
(14 days) treatment. Representative traces of sexual function during the
30-min sex test (x-axis) of individual rats (n = 1/group) treated with a
vehicle, b vilazodone, c citalopram, or d paroxetine (10 mg/kg) on day
14. Y-axis shows the events scored during the test (number of mounts,
intromissions, and ejaculations)
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citalopram, inhibited copulatory efficiency and ejaculatory
parameters (decreased frequency and increased latency to first
ejaculation). The paroxetine and citalopram results were con-
sistent with previous reports in rats (de Jong et al. 2005a, b;
Waldinger et al. 2002) and similar to humans (Waldinger et al.
2001). Since the 5-HT system maintains an inhibitory tone on
sexual behavior, chronic elevation of extracellular 5-HT by
SSRI treatment is believed to underlie delayed and inhibited
ejaculation in men (Rosen et al. 1999) and male rats (Chan et
al. 2010). Notably, the acute treatments had no effects on
sexual behavior which, given the inhibitory role of 5-HT in
sexual behaviors, may seem surprising. Acute administration
of SSRIs and vilazodone results in rapid and sharp increases in
extracellular 5-HT levels in the rat medial and lateral cortices
(van Amsterdam and Seyfried 2014) and in the ventral hippo-
campus (Page et al. 2002). The increase in 5-HT levels fol-
lowing vilazodone treatment was nearly two times greater
than following citalopram, paroxetine, or fluoxetine (van
Amsterdam and Seyfried 2014). However, evidence in
humans and rats suggests that acute treatments of SSRIs gen-
erally do not cause sexual dysfunction (Olivier et al. 2011;
Waldinger et al. 2001, 2002); rather, SSRI-related sexual dys-
function is likely dependent upon delayed neurochemical
adaptions following chronic, but not acute, elevation of 5-
Fig. 4 Effects of chronic (14 days) vilazodone, citalopram, and paroxe-
tine treatment on the levels of serotonergic markers in rat forebrain re-
gions. CP-M indicates caudate putamen-medial, CP-L caudate putamen-
lateral, DFC dorsal frontal cortex, EC entorhinal cortex, HIPP-CA1 hip-
pocampus CA1 region, HIPP-CA3 hippocampus CA3 region, MPC me-
dial prefrontal cortex, NAc nucleus accumbens. Data are shown as the
mean ± SEM (n = 8/group). *P < .05 vs vehicle (ANOVA, post hoc
Dunnett t test)
Table 1 Mean percent changes from vehicle in serotonergic markers
after chronic (14 days) vilazodone, citalopram, and paroxetine treatment
Brain region Vilazodone (%) Citalopram (%) Paroxetine (%)
3 mg/kg 10 mg/kg 10 mg/kg 10 mg/kg
5-HT1A
MPC −31* −32* NS NS
HIPP-CA1 −49* −49* +21* +20*
HIPP-CA3 −49* −42* +33* +34*
EC −42* −42* +39* +24*
5-HT2A
MPC +22* +23* NS +19*
DFC NS +21* +21* +19*
5-HTT
MPC −28* −49* −82* −91*
DFC −28* −42* −82* −91*
NAc −48* −50* −81* −90*
CP-M −37* −41* −69* −78*
CP-L −36* −37* −72* −79*
HIPP-CA1 −41* −45* −54* −72*
HIPP-CA3 −51* −55* −71* −87*
EC −45* −58* −71* −88*
CP-M caudate putamen-medial,CP-L caudate putamen-lateral,DFC dor-
sal frontal cortex, EC entorhinal cortex, HIPP-CA1 hippocampus CA1
region,HIPP-CA3 hippocampus CA3 region,MPCmedial prefrontal cor-
tex, NAc nucleus accumbens, NS not significantly different from vehicle
*P< .05 versus vehicle (n= 8/group)
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HT as well as modulations of neuroendocrine and other neu-
rotransmitter systems (Clayton et al. 2013; Olivier et al. 2011).
One notable exception may be the SSRI, dapoxetine, which
has been developed for the treatment of premature ejaculation.
The acute effects of dapoxetine on ejaculatory function have
been attributed to its pharmacokinetic profile (i.e., rapid ab-
sorption and elimination) and its targeting of excitatory tha-
lamic and hypothalamic regions associated with ejaculatory
response (Clément et al. 2012; McMahon 2011). However,
although one preclinical study found high-dose dapoxetine
to have limited effects on ejaculation latency in rapid-
ejaculating rats, other studies in normal male rats did not show
differences between dapoxetine and paroxetine (Olivier
2015). From this standpoint, dapoxetine does not appear to
differ from other SSRIs in its pharmacologic ability to inhibit
ejaculation latency in either rats or men (Olivier 2015). In
contrast to vilazodone, acute administration of 5-HT1A recep-
tor agonists stimulates copulatory and ejaculatory behaviors in
male rats (Arnone et al. 1995; de Jong et al. 2005b; Snoeren et
al. 2014), which may be due to the differences between full
and partial agonism at the 5-HT1A receptor; other differences
in acute neurophysiological and behavioral responses in rats
have been reported between full 5-HT1A receptor agonists and
vilazodone (Bartoszyk et al. 1997; Page et al. 2002).
Since the impetus for this study was to better understand
the adverse effects of SSRIs and other antidepressants on sex-
ual functioning in patients who require such treatments, the
current study focused on brain regions in the limbic system
known to be associated with MDD and SSRI-mediated sexual
dysfunction (Baldessarini 2006; Snoeren et al. 2014).
However, it is important to note that other structures rich in
5-HT receptors, such as the raphé magnus, raphé pallidus, and
gigantocelluar nuclei of the ventral medulla, may also contrib-
ute to the effects of antidepressants on male sexual behavior.
Studies in rats have reported various effects of SSRIs on 5-HT
receptor density. For example, repeated citalopram exposure
was found to increase 5-HT1A receptors and decrease 5-HT2A
receptors in the hippocampus in one study (Klimek et al.
1994), while a later study using positron emission tomography
along with autoradiographic assays found no effect of chronic
citalopram on 5-HT1A receptor density in the dorsal raphé
nucleus, frontal cortex, or hippocampus (Moulin-Sallanon et
al. 2009). Repeated administration with paroxetine in rats was
shown to have no effect on the density of 5-HT1A receptors in
the hypothalamus (Li et al. 1997). In the current study, chronic
vilazodone treatment reduced postsynaptic 5-HT1A receptor
levels in the cortical and hippocampal regions, while
citalopram and paroxetine increased 5-HT1A receptor levels
in the same brain regions. Importantly, the differential effects
of the drugs on postsynaptic 5-HT1A receptor levels occurred
in the limbic cortex (MPC and EC) and the hippocampus.
These are key brain substrates that receive afferent 5-HT pro-
jections from the dorsal and median raphé nucleus and are
involved in the regulation of ejaculation (Snoeren et al.
2014). Stimulation of postsynaptic 5-HT1A receptors by
vilazodone via both direct activation and elevated extracellu-
lar 5-HT levels in the prefrontal cortex and hippocampus
(Hughes et al. 2005; Page et al. 2002) may lead to 5-HT1A
receptor downregulation.
The results of 5-HT1A receptor downregulation and lack of
sexual side effects with vilazodone may complement a recent
electrophysiology study by Ashby et al. This study reported
that presynaptic 5-HT1A autoreceptors in the dorsal raphé nu-
clei, which normally inhibit 5-HT neuron firing, showedmuch
greater desensitization following chronic vilazodone treatment
than following a similar treatment with fluoxetine (Ashby et
al. 2013). Therefore, this desensitization would be expected to
increase extracellular 5-HT release in afferent brain regions,
including the cortex and hippocampus, and consequently re-
sult in a higher likelihood of sexual side effects following
chronic vilazodone administration compared with convention-
al SSRIs. However, one possible explanation for the lack of
sexual side effects of vilazodone is that the 5-HT1A partial
agonist activity of this molecule may stimulate the postsynap-
tic 5-HT1A receptors which can counteract the inhibitory ef-
fects of elevated extracellular 5-HT resulting from presynaptic
5-HT1A receptor desensitization and 5-HTT blockade. In ac-
cordance with this explanation, systemic administration of
several other 5-HT1A receptor agonists and partial agonists
enhanced ejaculatory behaviors in male rodents (Arnone et
al. 1995; de Jong et al. 2005b; Snoeren et al. 2014). For in-
stance, de Jong et al. (2005b) reported that a challenge with the
full 5-HT1A receptor agonist 8-OH-DPAT in male rats chron-
ically treated with paroxetine restored the sexual behavior of
these animals. Vilazodone has demonstrated comparable ac-
tivity to 8-OH-DPAT at postsynaptic 5-HT1A receptors in hip-
pocampal tissue (Hughes et al. 2005). If this hypothesis is
correct, the timing of the sexual behavior tests in rats relative
to drug administration may be critical and will be investigated
in a future study. In humans, however, this may be less of an
issue because of the much longer half-life of vilazodone.
Chronic treatment with vilazodone, citalopram, and parox-
etine reduced 5-HTT levels in all of the tested forebrain re-
gions. This is consistent with existing literature demonstrating
that elevated extracellular 5-HT concentrations in vitro
(Jorgensen et al. 2014) and chronic SSRI and serotonin nor-
epinephrine reuptake inhibitor (SNRI) treatment in vivo
(Mirza et al. 2007) can lead to reduced 5-HTT expression. A
consequence of reduced 5-HTT availability is enhanced post-
synaptic serotonergic neurotransmission, which may in turn
contribute to sexual dysfunction (Chan et al. 2011). In the
current study, the magnitude of reductions in 5-HTT levels
was greater for citalopram and paroxetine (maximum reduc-
tions of 80 and 91 %, respectively) than for vilazodone (max-
imum reduction of 58%). Because of the differential effects of
vilazodone relative to the SSRIs on both 5-HTT and 5-HT1A
1032 Psychopharmacology (2016) 233:1025–1034
receptors, it is likely that the dynamics of extracellular 5-HT
differ between rats that are chronically treated with the two
different types of antidepressants.
The increases in cortical 5-HT2A receptor levels following
the different types of antidepressant treatments may suggest a
commonmechanism of action that mediates the beneficial ther-
apeutic effects of dissimilar antidepressant drugs. The 5-HT2A
receptor is purported to have an inhibitory role in copulatory
behavior, as shown by a decreased number of rats that initiated
copulation after receiving 5-HT2A receptor agonists in a sexual
behavior test (Olivier et al. 2011). During the day 14 sexual
behavior tests, the majority of citalopram- and paroxetine-
treated rats had ≤2 ejaculations and several rats had no ejacu-
lations. These results may be related to elevated 5-HT2A recep-
tor activity following increased expression in cortical areas.
Conclusion
SSRI treatment is associated with direct negative effects on
sexual function that may lead to treatment discontinuation and
reduced quality of life (Hu et al. 2004). Combination therapy
with SSRIs and 5-HT1A agonists and partial agonists, such as
buspirone, has been shown to ameliorate SSRI-induced sexual
dysfunction (Clayton and Montejo 2006; Landen et al. 1999).
In the current preclinical studies, unlike the conventional
SSRIs, vilazodone was not associated with diminished copu-
latory or ejaculatory behaviors in male rats. These results sup-
port clinical trial data showing that vilazodone treatment,
while effective in improving depressive symptoms, was asso-
ciated with a relatively low incidence of direct adverse effects
on sexual function (Clayton et al. 2013, 2015). The distinct
effects of vilazodone on the 5-HTT and 5-HT1A receptors may
enhance serotonergic transmission to achieve clinical efficacy
in depression while limiting the adverse events of SSRI-
induced sexual dysfunction.
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